NASDAQ: EYPT - EyePoint Pharmaceuticals, Inc.

Yield per half year: -57.83%
Sector: Healthcare

Share chart EyePoint Pharmaceuticals, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Фармацевтическая компания EyePoint Pharmaceuticals, Inc. занимается разработкой и коммерциализацией терапевтических средств для улучшения жизни пациентов с серьезными заболеваниями глаз в США, Китае и Великобритании. Его коммерческие продукты включают YUTIQ для лечения хронического неинфекционного увеита, поражающего задний сегмент глаза; и DEXYCU для лечения послеоперационного воспаления.

More details
В разработке компании используется технология Durasert для устойчивой внутриглазной доставки лекарств, в том числе EYP-1901, экспериментальный интравитреальный препарат с устойчивой доставкой, который находится на второй фазе клинических испытаний. Ранее компания называлась pSivida Corp., а в марте 2018 года сменила название на EyePoint Pharmaceuticals, Inc.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

P/S 7.53
P/BV 18.41
EV/EBITDA -4.1
EBITDA -0.0443
Цена ао 8.44
Сайт https://eyepointpharma.com
Выручка 0.0204
ISIN US30233G2093
Число акций ао 0.0389 млрд
Валюта usd
IPO date 2005-01-27
Sector Health Care
Industry Pharmaceuticals
Валюта отчета usd
Change price per day: 0% (8.83)
Change price per week: +1.38% (8.71)
Change price per month: -2.97% (9.1)
Change price per 3 month: -16.22% (10.54)
Change price per half year: -57.83% (20.94)
Change price per year: +9.01% (8.1)
Change price per 3 year: -17.4% (10.69)
Change price per 5 year: +451.88% (1.6)
Change price per year to date: +44.28% (6.12)
All parameters

Underestimation

Title Value Grade
P/S 19.09 1
P/BV 3.3 5
P/E 0 0
EV/EBITDA -8.23 0
Total: 2

Efficiency

Title Value Grade
ROA, % -19.93 0
ROE, % -26.58 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0747 10
Total: 7.2

Growth impulse

Title Value Grade
Yield Revenue, % 125.58 10
Yield Ebitda, % 65.23 8
Yield EPS, % -68.68 0
Total: 4.2
More

ETF Share, % Profitability for 1 year, % Dividends, %
ProShares Ultra Nasdaq Biotechnology 0.03087 51.697637072723 0.85651
Fidelity MSCI Health Care Index ETF 0.00656 16.20294599018 1.46057
Goldman Sachs ActiveBeta US Small Cap Equity ETF 0.0189 31.359936575053 1.41955
ProShares Hedge Replication ETF 0.00271 5.9237999659878 1.47892
Humankind US Stock ETF 0.00348 18.809430395549 1.99919
Invesco Nasdaq Biotechnology ETF 0.04684 28.578975171685 0.8565
iShares Morningstar Small-Cap ETF 0.00701 30.095066471445 1.60498
iShares Morningstar Small-Cap Growth ETF 0.01385 33.628071953382 0.72598
iShares Micro-Cap ETF 0.11302 34.327031588619 1.54048
iShares Russell 2000 Growth ETF 0.01526 38.042556988 0.6026
iShares Russell 3000 ETF 0.00068 31.230028873917 1.43482
iShares Morningstar Small-Cap ETF 0.00701 391.25300933451 1.60498
iShares Morningstar Small-Cap Growth ETF 0.01385 682.83677107207 0.72598
Nuveen ESG Small-Cap ETF 0.04604 27.987510644337 1.41019
Direxion Daily Pharmaceutical & Medical Bull 3X Shares 0.59565 86.715867158672 1.2989
SPDR Portfolio MSCI Global Stock Market ETF 0.00225 23.658352229781 2.19607
ProShares UltraPro Russell2000 0.00963 89.821266282945 1.47873
Vanguard U.S. Momentum Factor ETF 0.11 45.845704753962 1.05834
Vanguard Russell 3000 ETF 0 31.87314172448 1.43817
Vanguard Russell 2000 Growth ETF 0.02 37.361289927043 0.60264
Vanguard Russell 2000 ETF 0.02 32.773459189339 1.48801
SPDR S&P Pharmaceuticals ETF 0.7819 29.798803697662 1.29889
Principal Healthcare Innovators ETF 0.04656 618.4964157054 0.8416
Future Tech ETF 0.04656 426.33969118983 0.8416



Head Job title Payment Year of birth
Dr. Jay S. Duker M.D. President, CEO & Director 848.5k 1959 (65 years)
Mr. Michael Pine Chief Business Officer 764.85k 1977 (47 years)
Mr. George O. Elston Executive VP & CFO 743.86k 1965 (59 years)
Mr. Ron I. Honig Esq. Chief Legal Officer & Company Secretary N/A
Ms. Jennifer Leonard Chief People Officer & Senior VP of IT N/A
Ms. Isabelle Lefebvre Chief Regulatory Officer N/A
Mr. Michael J. Maciocio Senior Vice President of Manufacturing & Operations N/A
Dr. John B. Landis M.S., Ph.D. Interim Head of R&D and Director 63.75k 1953 (71 year)
Mr. David Scott Jones M.A. Senior VP & Chief Commercial Officer 1967 (57 years)
Dr. Marcia Sellos-Moura Ph.D. Senior VP and Head of Development & Program Management

Address: United States, Watertown. MA, 480 Pleasant Street - open in Google maps, open in Yandex maps
Website: https://eyepointpharma.com